Development of Novel Therapies for Diabetic Ischemic Diseases using Secreted Factors from Stem Cells

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K08874
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 54040:Metabolism and endocrinology-related
• Research Institution: Aichi Medical University
• Principal Investigator: Kamiya Hideki 愛知医科大学, 医学部, 教授 (70542679)
• Co-Investigator(Kenkyū-buntansha): 恒川 新 愛知医科大学, 医学部, 准教授 (40612768)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: 再生医療 / ヒト乳歯歯髄幹細胞 / ヒト臍帯静脈内皮細胞

Outline of Final Research Achievements

Diabetes is a major risk factor for ischemic vascular diseases.
Here, we investigated the possibility of stem cells from human exfoliated deciduous teeth (SHED) for regenerative medicine. Conditioned medium collected from SHED (SHED-CM) significantly increased the viability and migration of human umbilical vein endothelial cells (HUVECs) and induced complex tubular structures of HUVECs. Furthermore, SHED-CM significantly increased neovascularization from the primary rat aorta, indicating that SHED-CM stimulated primary endothelial cells to promote comprehensive angiogenesis processes.
We can expect that SHED-CM is a useful therapeutic resource for diabetic ischemic diseases in future clinical applications.

Free Research Field

糖尿病

Academic Significance and Societal Importance of the Research Achievements

糖尿病は心血管疾患および重症下肢虚血などの虚血性疾患の重要な危険因子である。近年，虚血性疾患の新たな治療法として再生医療が期待されている。今回我々は、ヒト乳歯歯髄幹細胞（SHED）培養上清（SHED-CM）には血管内皮細胞を直接刺激して血管新生の全ての過程を促進することを示すことができた。このことを考慮すると、SHED-CMはSHED自体を直接組織に移植する治療法に比べて安全でまた効率的であることから、SHED-CMは虚血性疾患に対し臨床応用が期待される治療リソースと考えられる。今後の研究の発展を継続していきたい。